BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

609 related articles for article (PubMed ID: 18724391)

  • 1. Nausea and vomiting with high-dose chemotherapy and stem cell rescue therapy: a review of antiemetic regimens.
    Trigg ME; Inverso DM
    Bone Marrow Transplant; 2008 Oct; 42(8):501-6. PubMed ID: 18724391
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical practice guidelines on antiemetics in oncology.
    Aranda Aguilar E; Constenla Figueiras M; Cortes-Funes H; Diaz-Rubio García E; Gascon Vilaplana P; Guillém V; Martin-Algarra S
    Expert Rev Anticancer Ther; 2005 Dec; 5(6):963-72. PubMed ID: 16336087
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Double-blind comparative trial of oral ondansetron versus oral granisetron versus IV ondansetron in the prevention of nausea and vomiting associated with highly emetogenic preparative regimens prior to stem cell transplantation.
    Fox-Geiman MP; Fisher SG; Kiley K; Fletcher-Gonzalez D; Porter N; Stiff P
    Biol Blood Marrow Transplant; 2001; 7(11):596-603. PubMed ID: 11760147
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of aprepitant in patients receiving high-dose chemotherapy with hematopoietic stem cell support.
    Paul B; Trovato JA; Thompson J; Badros AZ; Goloubeva O
    J Oncol Pharm Pract; 2010 Mar; 16(1):45-51. PubMed ID: 19525301
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of second-generation 5-HT3 receptor antagonists in managing chemotherapy-induced nausea and vomiting in hematological malignancies.
    Schwartzberg LS; Jacobs P; Matsouka P; Azevedo W; Pinto A
    Crit Rev Oncol Hematol; 2012 Jul; 83(1):59-70. PubMed ID: 22321726
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nurses' perceptions of antiemetic effectiveness.
    Rhodes VA; McDaniel RW; Simms SG; Johnson M
    Oncol Nurs Forum; 1995 Sep; 22(8):1243-52. PubMed ID: 8532549
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk-benefit of antiemetics in prevention and treatment of chemotherapy-induced nausea and vomiting.
    Herrstedt J
    Expert Opin Drug Saf; 2004 May; 3(3):231-48. PubMed ID: 15155151
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk factors and antiemetic management of chemotherapy-induced nausea and vomiting.
    Goodman M
    Oncol Nurs Forum; 1997 Aug; 24(7 Suppl):20-32. PubMed ID: 9282378
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neurokinin-1-receptor antagonists: a new approach in antiemetic therapy.
    Jordan K
    Onkologie; 2006 Feb; 29(1-2):39-43. PubMed ID: 16514255
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemotherapy-induced nausea and vomiting: antiemetic trials that impacted clinical practice.
    Trigg ME; Higa GM
    J Oncol Pharm Pract; 2010 Dec; 16(4):233-44. PubMed ID: 20085961
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [New developments in the treatment of nausea and vomiting caused by chemotherapy].
    de Wit R; van Alphen MM
    Ned Tijdschr Geneeskd; 2003 Apr; 147(15):690-4. PubMed ID: 12722531
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimising antiemetic therapy: what are the problems and how can they be overcome?
    Aapro M
    Curr Med Res Opin; 2005 Jun; 21(6):885-97. PubMed ID: 15969889
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The efficacy and cost effectiveness of new antiemetic guidelines.
    Engstrom C; Hernandez I; Haywood J; Lilenbaum R
    Oncol Nurs Forum; 1999 Oct; 26(9):1453-8. PubMed ID: 11064877
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management of platinum-based chemotherapy-induced acute nausea and vomiting: is there a superior serotonin receptor antagonist?
    Hamadani M; Chaudhary L; Awan FT; Khan JK; Kojouri K; Ozer H; Tfayli A
    J Oncol Pharm Pract; 2007 Jun; 13(2):69-75. PubMed ID: 17873106
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiemetic effect of ondansetron and dexamethasone in gynecologic malignant patients receiving chemotherapy.
    Pradermdee P; Manusirivithaya S; Tangjitgamol S; Thavaramara T; Sukwattana P
    J Med Assoc Thai; 2006 Oct; 89 Suppl 4():S29-36. PubMed ID: 17725140
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Granisetron: an update on its clinical use in the management of nausea and vomiting.
    Aapro M
    Oncologist; 2004; 9(6):673-86. PubMed ID: 15561811
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized study of aprepitant, ondansetron and dexamethasone for chemotherapy-induced nausea and vomiting in Chinese breast cancer patients receiving moderately emetogenic chemotherapy.
    Yeo W; Mo FK; Suen JJ; Ho WM; Chan SL; Lau W; Koh J; Yeung WK; Kwan WH; Lee KK; Mok TS; Poon AN; Lam KC; Hui EK; Zee B
    Breast Cancer Res Treat; 2009 Feb; 113(3):529-35. PubMed ID: 18327706
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evolving roles of oncology pharmacists in Singapore: a survey on prescribing patterns of antiemetics for chemotherapy induced nausea and vomiting (CINV) at a cancer centre.
    Chan A; Shih V; Chew L
    J Oncol Pharm Pract; 2008 Mar; 14(1):23-9. PubMed ID: 18337437
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemotherapy-induced nausea and vomiting: prevention, detection, and treatment--how are we doing?
    Grunberg SM
    J Support Oncol; 2004; 2(1 Suppl 1):1-10, inside back cover; quiz 11. PubMed ID: 16117016
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aprepitant for the control of chemotherapy induced nausea and vomiting in adolescents.
    Smith AR; Repka TL; Weigel BJ
    Pediatr Blood Cancer; 2005 Nov; 45(6):857-60. PubMed ID: 15849684
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.